Data demonstrates Ronapreve reduced risk of hospitalisation in certain patients and reduced risk of symptomatic Covid-19 infections in people exposed to the virus
A final decision regarding the approval of Ronapreve is expected from the European Commission shortly
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
Solara Active Pharma Sciences has reported consolidated financial results for the period ended September 30, 2021.
J. B. Chemicals & Pharmaceuticals Limited (JBCPL), announced its financial results for the second quarter ended 30th September, 2021
Evidence also shows better immune response to virus among users of spray
Thermo Fisher Scientific expands diagnostics portfolio to support full qPCR assay development and testing workflow
Cipla Technologies a subsidiary of Cipla and Pulmatrix had inked a definitive agreement for the co-development and commercialisation of Pulmazole.
Molnupiravir is an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in at risk adults
Bioanalytical approach to accelerate development efforts in the identification of compounds that can treat chlorine or sulfur mustard injuries
Subscribe To Our Newsletter & Stay Updated
